Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Epic, Avera Ink Deal to Use Liquid Biopsy Platform in Clinical Studies

Epic, Avera Ink Deal to Use Liquid Biopsy Platform in Clinical Studies

Jan 28, 2016
|
staff reporter

NEW YORK (GenomeWeb) – Epic Sciences and Avera Medical announced today that they have signed a deal under which the healthcare network will use the company's circulating tumor cell (CTC)-detection and -analysis platform in upcoming clinical studies of precision cancer therapies.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

May
06
Featured Webinar

The Role of Single-Cell Functional Biomarkers in Next-Generation Cancer Therapies

Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.

What's Popular?

In Cancer

  1. Stanford Team Debuts New Liquid Biopsy Lung Cancer Screening Method

    Premium

  2. Grail Multi-Cancer Test Meets Validation Goals; Patients to Receive Results Under New Pilot

    Premium

  3. New Method for Detecting Point Mutations Could Significantly Impact Low-Cost Diagnostics

    Premium

  4. Oncocyte Details Plans for Rapidly Expanded Test Menu

    Premium

  5. The Decade in Genomics: CRISPR, Single Cells, Long Reads, Clinical and Consumer Applications

    Premium

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.